incretin receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
=== Special requirement food === The Modular Operational Rations Enhancement (MORE) is issued as a supplement to meals for troops in extreme, demanding operational environments such as high-intensity training events. The Tailored Operational Training Meal (TOTM) first entered service in May 2001. It provides a lower calorie count (an average of 997 kilocalories) for less intensive training environments, such as classroom instruction. It replaces the earlier mess-hall bagged lunches, catered meals or field kitchens for field instruction. The TOTM allows troops to become familiar with the MRE and its contents without providing an excessive amount of calories to troops who will not necessarily burn them. It uses a transparent outer plastic bag with commercial markings rather than the MRE's tan plastic bag with standard markings. There are currently 3 different lists of twelve menus, making a total of 36 different meals. Each TOTM ration case is packed with a full menu of 12 assorted meals, weighs about 20 lbs (9 kg), and is 0.95 cubic feet (27 L). The TOTM has a more limited shelf-life than the MRE, with a duration of only 12 to 18 months. The Unitized Group Ration (UGR) is a ration much like the MRE, but expanded to feed large groups. It is the successor to the older A-ration, B-ration, and T-ration. It comes packed in sealed metal trays that are heated and then opened. The Food Packet, Survival, General Purpose, Improved (FPSGPI) is given to pilots and other servicemembers that may require a small, extremely portable food ration for emergencies.
=== EC 2.7.11: Protein-serine/threonine kinases === EC 2.7.11.1: non-specific serine/threonine protein kinase EC 2.7.11.2: [pyruvate dehydrogenase (acetyl-transferring)] kinase EC 2.7.11.3: dephospho-(reductase kinase) kinase EC 2.7.11.4: (3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)) kinase EC 2.7.11.5: [isocitrate dehydrogenase (NADP+)] kinase EC 2.7.11.6: [tyrosine 3-monooxygenase] kinase EC 2.7.11.7: myosin-heavy-chain kinase EC 2.7.11.8: Fas-activated serine/threonine kinase EC 2.7.11.9: Goodpasture-antigen-binding protein kinase EC 2.7.11.10: IkB kinase EC 2.7.11.11: cAMP-dependent protein kinase EC 2.7.11.12: cGMP-dependent protein kinase EC 2.7.11.13: protein kinase C EC 2.7.11.14: rhodopsin kinase EC 2.7.11.15: β-adrenergic-receptor kinase EC 2.7.11.16: G-protein-coupled receptor kinase EC 2.7.11.17: Ca2+/calmodulin-dependent protein kinase EC 2.7.11.18: myosin-light-chain kinase EC 2.7.11.19: phosphorylase kinase EC 2.7.11.20: elongation factor 2 kinase EC 2.7.11.21: polo kinase EC 2.7.11.22: cyclin-dependent kinase EC 2.7.11.23: [RNA-polymerase]-subunit kinase EC 2.7.11.24: mitogen-activated protein kinase EC 2.7.11.25: mitogen-activated protein kinase kinase kinase EC 2.7.11.26: tau-protein kinase EC 2.7.11.27: [acetyl-CoA carboxylase] kinase EC 2.7.11.28: tropomyosin kinase EC 2.7.11.29: low-density-lipoprotein receptor kinase EC 2.7.11.30: receptor protein serine/threonine kinase EC 2.7.11.31: [hydroxymethylglutaryl-CoA reductase (NADPH)] kinase EC 2.7.11.32: [pyruvate, phosphate dikinase] kinase EC 2.7.11.33: [pyruvate, water dikinase] kinase
He later intervenes—too late—when Nicole assaults Venetia, a grad he was recruiting with, and becomes complicit in Pierpoint’s decision to bury the incident. Robert’s mentor Clement dies and leaves him his apartment as inheritance. Robert also reconciles with his estranged father during a recruiting trip to Oxford. In series 3, Robert has spent months working with Lumi founder Henry Muck as Pierpoint underwrites their IPO. He wakes up after a tryst with Nicole to find her dead beside him, leaving him shaken and guilt-ridden. Eric pushes him through the Lumi IPO. He later embarks on an ayahuasca trip with Henry which helps him come to terms with both his mother and Nicole's deaths, as well as giving him a renewed outlook on life. He grows closer to Yasmin and later brings her on a road trip tied to his efforts to raise venture capital for Little Labs, a psilocybin startup. Despite declaring mutual love with Yasmin, Robert accepts her decision to marry Henry for security and influence. Henry agrees to give Robert the money he needs to raise for Little Labs. By the series’ end, Robert thrives in California, confidently pitching Little Labs to venture capitalists.
In 2006, sales of Guinness in Ireland and the United Kingdom declined 7 percent. Despite this, Guinness still accounts for more than a quarter of all beer sold in Ireland. By 2015, sales were on the rise in Ireland but flat globally. By 2023, Guinness had grown to become the most popular draught beer in the United Kingdom, with about 11% of all sales. Guinness began retailing in India in 2007. Guinness has a significant share of the African beer market, where it has been sold since 1827. About 40 percent of worldwide total Guinness volume is brewed and sold in Africa, with Foreign Extra Stout the most popular variant. Three of the five Guinness-owned breweries worldwide are located in Africa. The beer is brewed under licence internationally in several countries, including Nigeria, the Bahamas, Canada, Cameroon, Kenya, Uganda, South Korea, Namibia, and Indonesia. In 2017, Guinness teamed up with AB InBev to distribute Guinness in mainland China. China is the single biggest worldwide alcohol market, especially for imported craft beers like Guinness. In 2025, AB InBev started brewing Guinness under licence in China. Initial reception was not favourable, with one publican reportedly stating that the "feedback from everyone is that it tastes like cigarettes or an ashtray. The taste is not the same at all and the aftertaste is terrible". In November 2025, Diego announced a "double-digit" decline in sales in China. The United Kingdom is the only sovereign state to consume more Guinness than Ireland.
Sources: en.wikipedia.org
The enzyme 2-dehydro-3-deoxy-phosphogluconate aldolase (EC 4.1.2.14), commonly known as KDPG aldolase, catalyzes the chemical reaction 2-dehydro-3-deoxy-D-gluconate 6-phosphate ⇌ {\displaystyle \rightleftharpoons } pyruvate + D-glyceraldehyde 3-phosphate This enzyme belongs to the family of lyases, specifically the aldehyde-lyases, which cleave carbon-carbon bonds. It is used in the Entner–Doudoroff pathway in prokaryotes, feeding into glycolysis. 2-dehydro-3-deoxy-phosphogluconate aldolase is one of the two enzymes distinguishing this pathway from the more commonly known Embden–Meyerhof–Parnas pathway. This enzyme also participates in following 3 metabolic pathways: pentose phosphate pathway, pentose and glucuronate interconversions, and arginine and proline metabolism. In addition to the cleavage of 2-dehydro-3-deoxy-D-gluconate 6-phosphate, it is also found to naturally catalyze Schiff base formation between a lysine ε-amino acid group and carbonyl compounds, decarboxylation of oxaloacetate, and exchange of solvent protons with the methyl hydrogen atoms of pyruvate.
With the development of AMS in the 1980s it became possible to measure these isotopes precisely enough for them to be the basis of useful dating techniques, which have been primarily applied to dating rocks. Naturally occurring radioactive isotopes can also form the basis of dating methods, as with potassium–argon dating, argon–argon dating, and uranium series dating. Other dating techniques of interest to archaeologists include thermoluminescence, optically stimulated luminescence, electron spin resonance, and fission track dating, as well as techniques that depend on annual bands or layers, such as dendrochronology, tephrochronology, and varve chronology.
== Modifications == Before biosynthetic human recombinant analogues became available, porcine insulin was chemically modified to create human insulin. These semisynthetic insulins were produced by altering amino acid side chains at the N-terminus and C-terminus to modify absorption, distribution, metabolism, and excretion (ADME) characteristics. Novo Nordisk developed one such method by enzymatically converting porcine insulin into human insulin by replacing the single differing amino acid. Unmodified human and porcine insulins naturally form hexamers with zinc, requiring dissociation into monomers before binding to insulin receptors. This delays insulin activity when injected subcutaneously, making it less effective for postprandial glucose control. Basal insulin analogues were developed with altered isoelectric points, allowing them to precipitate at physiological pH and dissolve slowly, providing insulin coverage for up to 24 hours. Some, like insulin detemir, bind to albumin rather than fat, prolonging their action. Non-hexameric (monomeric) insulins were later introduced for faster-acting mealtime coverage, mimicking naturally occurring monomeric insulins found in certain animal species. These advancements in insulin formulation allowed for greater flexibility in diabetes management, with basal insulin analogues providing steady background insulin levels and short-acting analogues offering improved postprandial glucose control.
Metabolic intermediates are compounds produced during the conversion of substrates (starting molecules) into final products in biochemical reactions within cells. Although these intermediates are of relatively minor direct importance to cellular function, they can play important roles in the allosteric regulation of enzymes, glycolysis, the citric acid cycle, and amino acid synthesis. Metabolic pathways consist of a series of enzymatically catalyzed reactions where each step transforms a substrate into a product that serves as the substrate for the next reaction. Metabolic intermediates are compounds that form during these steps, and they are neither the starting substrate nor the final product of the pathway. These intermediates are crucial because they allow for regulation, energy storage, and extraction of chemical energy in a controlled manner.
== Concurrent and perpendicular lines == The two diagonals and the two tangency chords are concurrent. One way to see this is as a limiting case of Brianchon's theorem, which states that a hexagon all of whose sides are tangent to a single conic section has three diagonals that meet at a point. From a tangential quadrilateral, one can form a hexagon with two 180° angles, by placing two new vertices at two opposite points of tangency; all six of the sides of this hexagon lie on lines tangent to the inscribed circle, so its diagonals meet at a point. But two of these diagonals are the same as the diagonals of the tangential quadrilateral, and the third diagonal of the hexagon is the line through two opposite points of tangency. Repeating this same argument with the other two points of tangency completes the proof of the result. If the extensions of opposite sides in a tangential quadrilateral intersect at J and K, and the diagonals intersect at P, then JK is perpendicular to the extension of IP where I is the incenter.
Sources: en.wikipedia.org
"Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome". European Journal of Endocrinology. 158 (6): 793–801. doi:10.1530/EJE-07-0857. PMID 18322300. Jensterle, Mojca; Janez, Andrej; Vrtovec, Bojan; Meden-Vrtovec, Helena; Pfeifer, Marija; Prezelj, Janez; Kocjan, Tomaz (2007). "Decreased Androgen Levels and Improved Menstrual Pattern after Angiotensin II Receptor Antagonist Telmisartan Treatment in Four Hypertensive Patients with Polycystic Ovary Syndrome: Case Series". Croatian Medical Journal. 48 (6): 864–70. doi:10.3325/cmj.2007.6.864. PMC 2213810. PMID 18074422. Silič, Anja; Janež, Andrej; Tomažič, Janez; Karner, Primož; Vidmar, Ludvik; Sharma, Prem; Matičič, Mojca (2007). "Effect of Rosiglitazone and Metformin on Insulin Resistance in Patients Infected with Human Immunodeficiency Virus Receiving Highly Active Antiretroviral Therapy Containing Protease Inhibitor: Randomized Prospective Controlled Clinical Trial". Croatian Medical Journal. 48 (6): 791–9. doi:10.3325/cmj.2007.6.791. PMC 2213797. PMID 18074413. Steiner, Charles A.; Janez, Andrej; Jensterle, Mojca; Reisinger, Katrin; Forst, Thomas; Pfützner, Andreas (2007). "Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome". Journal of Diabetes Science and Technology. 1 (2): 211–7. doi:10.1177/193229680700100212. PMC 2771474. PMID 19888409. Mlinar, B; Marc, J; Janez, A; Pfeifer, M (2007).
=== Signs and symptoms === Death caps have been reported to taste pleasant. This, coupled with the delay in the appearance of symptoms—during which time internal organs are being severely, sometimes irreparably, damaged—makes them particularly dangerous. Initially, symptoms are gastrointestinal in nature and include colicky abdominal pain, with watery diarrhea, nausea, and vomiting, which may lead to dehydration if left untreated, and, in severe cases, hypotension, tachycardia, hypoglycemia, and acid–base disturbances. These first symptoms resolve two to three days after the ingestion. A more serious deterioration signifying liver involvement may then occur—jaundice, diarrhea, delirium, seizures, and coma due to fulminant liver failure and attendant hepatic encephalopathy caused by the accumulation of normally liver-removed substances in the blood. Kidney failure (either secondary to severe hepatitis or caused by direct toxic kidney damage) and coagulopathy may appear during this stage. Life-threatening complications include increased intracranial pressure, intracranial bleeding, pancreatic inflammation, acute kidney failure, and cardiac arrest. Death generally occurs six to sixteen days after the poisoning. It is noticed that after up to 24 hours have passed, the symptoms seem to disappear and the person might feel fine for up to 72 hours. Symptoms of liver and kidney damage start 3 to 6 days after the mushrooms were eaten, with the considerable increase of the transaminases. Mushroom poisoning is more common in Europe than in North America.
=== Herbal Medicine === There are herbs that kill or interrupt the lifecycle of scabies mites both in the lab and when topically applied to living people. Despite this, curing the condition solely with herbal medicine is difficult and often not recommended, even by advocates of herbal medicine. There are many natural chemicals that are insecticides (bug killing), acaricides (tick and mite killing), miticides (mite killing), and/or scabicides (Scabies mite killing). Many herbal recepies exist to fight mite-caused diseases including the highly-related sarcoptic mange in other animals but they may claim only to treat symptoms, lessen severity, or prevent new infections. Interest in herbal and hybrid treatments is partially driven by concerns about drug-resistance. Herbs with documented scabicidal effects include thyme, majoram, clove, camphor tree, geranium, tea tree, rosemary, oregano, neem, and coconut. Herbal medicines that kill mites in lab settings may not be safe to apply topically at that concentration. These medicines may also not absorb through the skin well enough to kill mites in pustules, nodules, or burrows.
In enzymology, 4-aminobutyrate transaminase (EC 2.6.1.19), also called GABA transaminase or 4-aminobutyrate aminotransferase, or GABA-T, is an enzyme that catalyzes the reversible chemical reaction: GABA + α-ketoglutaric acid ⇌ {\displaystyle \rightleftharpoons } succinate semialdehyde + L-glutamic acid The two substrates of this enzyme are GABA and α-ketoglutaric acid. Its products are succinate semialdehyde and L-glutamic acid. Th enzyme is a transferase, specifically a transaminase, which transfer nitrogenous groups. The systematic name of this enzyme class is 4-aminobutanoate:2-oxoglutarate aminotransferase. This enzyme participates in 5 metabolic pathways: alanine and aspartate metabolism, glutamate metabolism, β-alanine metabolism, propanoate metabolism, and butanoate metabolism. It uses pyridoxal phosphate as a cofactor. This enzyme is found in prokaryotes, plants, fungi, and animals (including humans). Pigs have often been used when studying how this protein may work in humans.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.